Advertisement

Document › Details
Qiagen N.V.. (7/26/23). "Press Release: Bio-Rad and Qiagen Announce Patent Settlement and Cross-licensing Agreement". Venlo.
![]() |
Organisation | Qiagen N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) |
Group | Qiagen (Group) | |
Organisation 2 | Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) | |
Group | Bio-Rad (Group) | |
![]() |
Product | digital PCR technology (dPCR) |
Product 2 | IP services | |
![]() |
Person | Gilardi, John (Qiagen 201211 Investor Relations) |
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). In 2022, QIAGEN had net sales of more than $2.1 billion and over 6,200 employees. Further information can be found at http://www.qiagen.com.
BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.
QIAGEN is a trademark of QIAGEN N.V. in certain jurisdictions.
Edward Chung
Bio-Rad Laboratories, Inc.
510-741-6104
ir@bio-rad.com
Anna Gralinska
Bio-Rad Laboratories, Inc.
510-741-6643
cc@bio-rad.com
Press Contact
Daniela Eltrop
Associate Director Public Relations
Germany: +49 2103 29 11676
Mobile: +49 152 01811676
daniela.eltrop@qiagen.com
Lisa Mannagottera
Associate Manager Public Relations
Germany: +49 2103 29 14181
Mobile: +49 152 01811381
lisa.mannagottera@qiagen.com
Dr. Thomas Theuringer
Senior Director Corporate Communications & Head Of External
Germany: +49 2103 29 11826
U.S.: +1 240 686 7425
The Netherlands: +31 773 55 66 66
thomas.theuringer@qiagen.com
IR Contacts
Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
phoebe.loh@qiagen.com
Alexandra Koenig
Investor Relations Coordinator
+49 2103 29 11709
alexandra.koenig@qiagen.com
John Gilardi
Vice President
Head of Corporate Communications and Investor Relations
Germany +49 2103 29 11711
U.S. +1 240 686 2222
The Netherlands +31 773 55 66 66
john.gilardi@qiagen.com
Record changed: 2023-08-09 |
Advertisement

More documents for Qiagen (Group)
- [1] Qiagen N.V.. (9/11/23). "Press Release: Qiagen Launches API to Streamline Access to World-leading Biomedical Data for AI Integration". Venlo & Redwood City, CA....
- [2] Qiagen N.V.. (6/15/23). "Press Release: Qiagen’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-analysis of Tuberculosis Screening". Venlo....
- [3] Qiagen N.V.. (6/13/23). "Press Release: Danish National Genome Center Selects Qiagen for Variant Interpretation in Oncology Genome Sequencing". Venlo & Redwood City, CA....
- [4] Qiagen N.V.. (5/15/23). "Press Release: Qiagen Expands Enzyme Offering to Support Individual Life Science Research Labs Worldwide". Berlin....
- [5] Qiagen N.V.. (5/3/23). "Press Release: Qiagen Exceeds Outlook for Q1 2023 with 12% CER Sales Growth in Non-COVID Product Portfolio". Venlo....
- [6] Qiagen N.V.. (2/14/23). "Press Release: Qiagen’s Tuberculosis Blood Test QuantiFERON-TB Gold Plus Gains CE-marking Under New EU IVDR Framework". Venlo....
- [7] Qiagen N.V.. (2/7/23). "Press Release: Qiagen Exceeds Outlook for Fourth Quarter and Full-year 2022 with 14% CER Sales Growth in FY 2022 from Non-COVID Product Groups". Venlo....
- [8] Qiagen N.V.. (1/23/23). "Press Release: Qiagen Digital Insights Launches Ultra-fast NGS Analysis Able to Process a Whole Genome in 25 Minutes for a $1 in Cloud Computing Costs". Redwood City, CA & Hilden....
- [9] Qiagen N.V.. (1/17/23). "Press Release: Qiagen Launches EZ2 Connect MDx Platform for Automated Sample Processing in". Venlo....
- [10] Qiagen N.V.. (1/9/23). "Press Release: Qiagen Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics with NGS Technologies". Venlo & San Diego, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top